The AKAP8 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population of HT29 cells bearing a targeted disruption of the AKAP8 gene. This product provides a loss-of-function model system for investigating the roles of A-kinase anchoring protein 8 (AKAP8) in nuclear signaling, chromatin organization, and cell cycle regulation. Generated via CRISPR/Cas9-mediated gene knockout, the polyclonal pool captures a heterogeneous collection of edited alleles, enabling robust functional studies without single-cell clonal isolation. Researchers can utilize these cells to interrogate AKAP8-dependent processes in a colorectal adenocarcinoma background, gaining insights into the molecular underpinnings of cancer cell proliferation and nuclear matrix dynamics.
HT29 cells are a well-characterized human colorectal adenocarcinoma cell line with epithelial morphology, extensively employed as an intestinal epithelial model in colorectal cancer research. Derived from a primary tumor, these cells retain key features of colon carcinoma, including oncogenic mutations and dysregulated growth signaling, making them a physiologically relevant platform for studying tumorigenesis. Their adherent growth and well-documented genetic landscape facilitate reproducible experimentation and integration with diverse molecular and cellular assays. The HT29 background is particularly suited for examining how AKAP8 influences colorectal cancer progression, chromosomal instability, and response to therapeutic agents targeting the cAMP/PKA axis or DNA replication machinery.
AKAP8 functions as a scaffold protein that anchors protein kinase A (PKA) to the nuclear matrix through its RII-binding domain, thereby spatially organizing cAMP/PKA signaling within the nucleus. This anchoring facilitates PKA-mediated phosphorylation of chromatin-associated substrates, directly coupling cAMP fluctuations to DNA replication and cell cycle control. AKAP8 is activated by upstream regulators including cAMP and CDK1, and it interacts with PKA RII??, Ki-67, nucleolin, and topoisomerase II?? (TOP2A) to orchestrate nuclear events. Downstream, AKAP8 modulates phosphorylation of PKA substrates such as CREB and histone H3, as well as DNA replication factors, connecting cAMP signals to transcriptional regulation and replication origin firing. Representative pathway components like adenylate cyclase, PKA catalytic subunits, cyclin B, and the MCM complex further illustrate the molecular network in which AKAP8 operates.
In HT29 colorectal adenocarcinoma cells, disruption of AKAP8 is expected to impair spatially organized PKA signaling at the nuclear matrix, leading to dysregulation of DNA replication and cell cycle progression. This model enables dissection of how AKAP8-dependent phosphorylation events control chromatin dynamics and proliferative capacity in a cancer context. Because AKAP8 interacts with nuclear matrix proteins and cell cycle regulators, its knockout may expose vulnerabilities in chromosomal stability and DNA replication fidelity, offering a platform to study mechanisms of cancer progression. The polyclonal nature of the knockout population mitigates clonal artifacts, providing a more representative assessment of gene function across a mixed edited cell pool.
These AKAP8 knockout cells are suitable for a wide range of research applications, including investigation of PKA nuclear anchoring, colorectal cancer cell proliferation, and chromatin organization. They support assays such as western blotting and immunofluorescence to confirm protein loss and subcellular localization changes, RT-qPCR for transcriptional analysis, EdU incorporation and flow cytometry for cell cycle profiling, and co-immunoprecipitation or ChIP-qPCR to probe protein interactions and chromatin occupancy. Drug sensitivity assays using MTT or related viability readouts can be employed to evaluate AKAP8 as a therapeutic target. Researchers are invited to contact Ascent Research for further information on this product and its applications in advanced biomedical investigation.
